Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Are Biologics for COPD Around the Corner? A Quick Look at the Literature
No biologic agent is approved to treat COPD, but progress is being made. Key developments of the past few years are summarized in this brief slideshow.
Omalizumab, a monoclonal antibody, became the first biologic therapy for severe asthma when it received FDA approval in 2003. Since then, several other biologic therapies have become available for asthma treatment. No biologic therapy is currently approved for chronic obstructive pulmonary disease (COPD), but progress is being made.
Key developments of the past few years are summarized in the slides below.
Related Videos
Related Content
